This PubMed entry documents a 2026 Blood Advances article titled "Treatment-free remission and immune profiling after frontline second-generation TKI therapy in CML." The title indicates the study addresses clinical outcomes of treatment-free remission (TFR) and associated immune profiling following frontline use of second-generation tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia (CML).
The PubMed record confirms the article is available as a free article and provides bibliographic metadata (journal, date, volume, pages, DOI, PMID) and links to publisher full-text options. The content supplied here from PubMed focuses on bibliographic and authorship information rather than the study abstract or manuscript content.
The article lists Naoto Takahashi as first author and includes a large, multi-institutional Japanese author group. Affiliations reported on the PubMed page span at least 19 departments and institutions in Japan, including academic hematology departments, transplant registries, and medical centers (for example, Akita University Graduate School of Medicine; National Cancer Center Hospital East; Kanazawa University; Japanese Data Center for Hematopoietic Cell Transplantation; Nagasaki University; Nagoya University; Kyushu University; and other regional hospitals and centers).
The PubMed entry reports the following identifiers and citation details:
Based solely on the article title, the study’s scope appears to include two linked aims:
The title implies the authors investigated both clinical outcomes (TFR success/failure) and immunologic correlates, potentially to identify biomarkers or immune signatures related to sustained TFR after discontinuation of second-generation TKIs.
The provided PubMed content includes:
No abstract text, trial registration details, tables, figures, or numerical results are included in the supplied PubMed excerpt.
The PubMed snippet supplied does not contain the following essential information necessary to interpret clinical implications or apply findings to practice:
Because these details were not provided in the PubMed excerpt included here, they cannot be reported or summarized.
To obtain the complete study methods, results, and authors’ conclusions, consult the full text via the publisher links shown on the PubMed page (Blood Advances / Silverchair Information Systems and Elsevier links). The DOI (10.1182/bloodadvances.2026020915) and PMID (42314090) can be used to locate the article directly.
Clinicians and researchers seeking to apply or evaluate the study findings should review the full manuscript for:
This rewritten summary is restricted to the bibliographic and metadata available in the supplied PubMed page. Specific study data, results, and conclusions were not included in the source text provided and therefore are explicitly not reported here. For evidence-based interpretation, refer to the full published article and supplementary materials.